Altimmune (ALT) to Release Quarterly Earnings on Thursday

Altimmune (NASDAQ:ALT) is expected to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.0010 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

Altimmune Stock Performance

Shares of Altimmune stock opened at $4.57 on Wednesday. The company has a quick ratio of 17.18, a current ratio of 17.18 and a debt-to-equity ratio of 0.08. The stock’s fifty day moving average is $4.50 and its two-hundred day moving average is $4.26. Altimmune has a 52 week low of $2.90 and a 52 week high of $7.73. The company has a market capitalization of $515.63 million, a PE ratio of -4.27 and a beta of 0.09.

Analyst Ratings Changes

A number of research analysts have recently commented on ALT shares. Barclays started coverage on shares of Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price target on the stock. Citizens Jmp dropped their target price on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $17.60.

Insider Activity

In other Altimmune news, Director John Gill purchased 12,500 shares of the stock in a transaction dated Tuesday, December 23rd. The stock was purchased at an average price of $4.10 per share, with a total value of $51,250.00. Following the transaction, the director owned 12,500 shares of the company’s stock, valued at approximately $51,250. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jerome Benedict Durso acquired 12,500 shares of the company’s stock in a transaction dated Monday, December 22nd. The shares were acquired at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the purchase, the director owned 12,500 shares of the company’s stock, valued at approximately $51,625. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders bought 30,527 shares of company stock valued at $125,278. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Altimmune

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Altimmune by 23.3% in the 3rd quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock worth $24,029,000 after acquiring an additional 1,206,514 shares in the last quarter. State Street Corp grew its stake in Altimmune by 42.2% in the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock valued at $18,482,000 after purchasing an additional 1,518,448 shares during the last quarter. Geode Capital Management LLC raised its holdings in Altimmune by 13.6% in the fourth quarter. Geode Capital Management LLC now owns 2,292,410 shares of the company’s stock worth $8,278,000 after purchasing an additional 275,025 shares in the last quarter. Two Sigma Investments LP lifted its position in shares of Altimmune by 356.6% during the third quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after buying an additional 1,559,562 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Altimmune by 140.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,349,293 shares of the company’s stock valued at $4,871,000 after buying an additional 787,036 shares during the last quarter. Institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.